Cardiac Amyloidosis Registry of University Hospital Leipzig
This is a registry study at University Hospital Leipzig for people who have cardiac amyloidosis, a condition where abnormal protein builds up in the heart. The main goal is to collect detailed information about patients' symptoms, diagnostic tests, and the treatments they receive as part of their routine care. This helps researchers understand the condition better, including how it affects people over a long time and what impact other health problems might have. Standard drug trials often pick very specific patients, so this registry aims to get a truer picture of how cardiac amyloidosis affects a wider range of people in everyday healthcare. The information gathered will help improve diagnosis, treatment, and ongoing care for patients with this condition.
At a glance
What is this study about?
This study is called a 'registry,' which means it's a way for doctors and researchers at University Hospital Leipzig to collect and keep track of information from people living with a heart condition called cardiac amyloidosis. Think of it like a detailed record-keeping system for everyone who has this condition and is being treated at that hospital.
Cardiac amyloidosis happens when abnormal proteins build up in your heart, making it harder for your heart to work properly. While we're getting better at spotting this condition and have more treatment options, the information from traditional drug trials doesn't always tell the whole story. Those trials often involve a very specific group of patients, which might not reflect everyone living with cardiac amyloidosis in the real world, including those with other health issues or different treatment journeys.
By gathering information on things like symptoms, the results of different heart scans, blood tests, other health problems, and the treatments people receive as part of their regular care, this registry helps fill those gaps. The aim is to get a clearer, more complete picture of cardiac amyloidosis – how it affects people over time, how different treatments work, and how other health conditions might play a role. This vital information can help improve how doctors diagnose, treat, and care for people with cardiac amyloidosis in the future.
Key takeaways
- This is a registry (data collection study), not a treatment trial.
- It aims to understand cardiac amyloidosis better in real-world patients.
- Information from your routine medical care will be used.
- No new treatments or tests are involved.
- All ages and sexes with confirmed cardiac amyloidosis can be included.
- Your medical care will not be affected if you choose not to participate or withdraw.
Who may be eligible?
To be included in this ongoing registry, you would need to have a confirmed diagnosis of cardiac amyloidosis. This means your doctor has already confirmed you have the condition using current medical standards.
This registry is for anyone who meets the diagnosis criteria, regardless of their age or sex.
However, if for any reason you don't want your information to be included in the registry, you would not be able to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do I have a confirmed diagnosis of cardiac amyloidosis?
- Am I currently receiving treatment for cardiac amyloidosis at University Hospital Leipzig?
- Am I comfortable with my routine medical information being used for research?
- Do I understand that this is not a study testing new medication?
What does participation involve?
If you take part in this registry, you won't be given any new or experimental treatments. Instead, the study will gather information from your routine medical care for cardiac amyloidosis at University Hospital Leipzig. This means data from your regular check-ups, diagnostic tests like heart scans (echocardiograms), blood tests, and information about your symptoms, general health, and any treatments you receive will be collected. You won't have any extra visits, tests, or medication specifically for the registry; it simply uses the information already being gathered as part of your standard treatment. There is no set total duration for your participation, as data will be collected throughout your ongoing routine care at the hospital.
Potential risks and benefits
Locations (1)
- University Hospital LeipzigVerified postcodeLeipzig, Germany· Recruiting
Common questions
What is cardiac amyloidosis?
Cardiac amyloidosis is a heart condition where abnormal proteins build up in the heart muscle, making it stiff and harder for it to pump blood effectively.
Is this a drug trial?
No, this is not a drug trial. It's a registry, meaning it collects information from people undergoing routine medical care for their condition, rather than testing new treatments.
Will I receive new treatments if I join?
No, you will not receive any new or experimental treatments by joining this registry. You will continue with your standard medical care for cardiac amyloidosis.
How will my personal information be kept safe?
The study takes patient privacy very seriously. All your personal data will be kept confidential and handled securely according to strict guidelines.
Can I decide not to participate later?
Yes, you are free to withdraw your consent for your data to be included in the registry at any point without it affecting your medical treatment.
How to find out more
Daniel Lavall, MD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.